Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoStart with Pro — $79/mo
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Executive ChangeItem 5.02 · 8-KLOW RiskPositive

CANDEL THERAPEUTICS, INC.

www.candeltx.com
Filed: Jun 23, 2026CIK: 001-40629Health Care
Watch CompanyView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Candel Therapeutics held its Annual Meeting of Stockholders on June 23, 2026, electing four new Class II directors to serve until 2029 and ratifying KPMG LLP as the independent auditor. This routine governance event reflects normal board succession and audit oversight.

Key Takeaways

Four Class II directors were elected: Edward J. Benz Jr. M.D., Paul B. Manning, Maha Radhakrishnan M.D., and Paul Peter Tak M.D., Ph.D., FMedSci, serving until the 2029 annual meeting

KPMG LLP was ratified as the company's independent auditor for the fiscal year

1 more takeaway

Filing Overview

Form Type8-K
Filing DateJun 23, 2026
Item5.02
CategoryExecutive Change
CIK001-40629
Accession #0001841387
Risk LevelLOW
SentimentPositive
Signalinformational
Topics
board changeleadership transition

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings